{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:06:05Z","timestamp":1773147965511,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T00:00:00Z","timestamp":1515369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>\n                    An increase in fracture risk has been reported in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin, possibly mediated by effects induced by all members of the sodium\u2010glucose co\u2010transporter\u20102 (SGLT2) inhibitor class. It is unclear whether initiation of dapagliflozin is followed by an increase in the risk of fracture; therefore, we performed a population\u2010based, open cohort study (from January 2013 to January 2016) using The Health Improvement Network (THIN). A total of 22 618 people with T2DM (4548 exposed to dapagliflozin and 18 070 receiving standard antidiabetic treatment, matched for age, sex, body mass index and diabetes duration) with no history of fractures at baseline were included. The primary outcome was the occurrence of any fragility fracture (hip, spine, wrist) during the observation period. Risk of any fracture served as a secondary outcome. Adjusted hazard rate ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox regression. A total of 289 fractures (132 fragility fractures) were recorded. No difference in the risk of fragility fracture was detected between participants prescribed dapagliflozin and matched control participants (crude HR 0.90, 95% CI 0.59\u20101.39,\n                    <jats:italic>P<\/jats:italic>\n                    = .645; adjusted HR 0.87, 95% CI 0.56\u20101.35,\n                    <jats:italic>P<\/jats:italic>\n                    = .531). Similarly, no difference in the risk of any fracture was detected (adjusted HR 0.89, 95% CI 0.66\u20101.20;\n                    <jats:italic>P<\/jats:italic>\n                    = .427). Sensitivity analyses limited to the subset of the population at high risk of fracture produced similar results; thus, there was no evidence to suggest an increase in the risk of treatment\u2010emergent fractures in patients with T2DM who initiated treatment with dapagliflozin.\n                  <\/jats:p>","DOI":"10.1111\/dom.13176","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T02:06:39Z","timestamp":1512007599000},"page":"1070-1074","source":"Crossref","is-referenced-by-count":35,"title":["Initiation of dapagliflozin and treatment\u2010emergent fractures"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2044-4253","authenticated-orcid":false,"given":"Konstantinos A.","family":"Toulis","sequence":"first","affiliation":[{"name":"Institute of Applied Health Research University of Birmingham  Birmingham UK"},{"name":"Department of Endocrinology 424 General Military Hospital  Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[{"name":"Metabolic Bone Diseases Unit, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons Columbia University  New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Neil","family":"Thomas","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research University of Birmingham  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasim","family":"Hanif","sequence":"additional","affiliation":[{"name":"Diabetes Department University Hospitals Birmingham NHS Foundation Trust  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalliopi","family":"Kotsa","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Division of Endocrinology &amp; Diabetes Center Aristotle University  Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasiah","family":"Thayakaran","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research University of Birmingham  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepiksana","family":"Keerthy","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research University of Birmingham  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9037-1937","authenticated-orcid":false,"given":"Abd A","family":"Tahrani","sequence":"additional","affiliation":[{"name":"Institute of Metabolism and Systems Research University of Birmingham  Birmingham UK"},{"name":"Centre for Endocrinology, Diabetes and Metabolism Birmingham Health Partners  Birmingham UK"},{"name":"Department of Diabetes and Endocrinology Birmingham Heartlands Hospital  Birmingham B15 2TT UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnarajah","family":"Nirantharakumar","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Research University of Birmingham  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.7.1192"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2012.11.010"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1860"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3167"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.356"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01630.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12189"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3446"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.080486"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.04.055"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70227-X"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamainternmed.469"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13176","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:41:11Z","timestamp":1761867671000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,8]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/dom.13176"],"URL":"https:\/\/doi.org\/10.1111\/dom.13176","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,8]]}}}